Metagenomi Therapeutics, Inc. (MGX) News
Follow Metagenomi Therapeutics, Inc. (MGX) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 5 public stories across 4 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Metagenomi advances MGX-001 toward IND filing
Metagenomi said MGX-001 has preclinical durability and safety data and plans to file an IND in Q4 2026. The company said it had $120.7 million of cash runway through Q4 2027.
EQUITY | Sep 22, 2026, 10:03 AM UTC
L
MGX advances Central Tanami JV amid strong cash and no debt
MGX says it is advancing the Central Tanami Project JV, citing a strong cash position and no debt. The company is developing Groundrush and Jims deposits and planning to exit iron ore to focus on precious metals.
COMMODITIES | Sep 03, 2026, 10:29 PM UTC
L
Metagenomi Therapeutics to present at Wells Fargo 21st Healthcare conference
Metagenomi Therapeutics, Inc. announced that Jian Irish, Ph.D., M.B.A., will present at the Wells Fargo 21st Annual Healthcare Conference.
EQUITY | Sep 01, 2026, 12:07 PM UTC
L
MGX to present at Wells Fargo 21st Annual Healthcare Conference
Metagenomi Therapeutics (MGX) plans to present at the Wells Fargo 21st Annual Healthcare Conference.
EQUITY | Sep 01, 2026, 12:00 PM UTC
L
MGX - Did Metagenomi Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
MGX - Did Metagenomi Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
EQUITY | Aug 25, 2026, 02:13 PM UTC